APACMed Implements Universal Code of Ethical Conduct for Corporate Members

SINGAPORE, Dec. 11, 2015 /PRNewswire/ -- The Asia Pacific Medical Technology Association (APACMed), announced today that it has approved a new Code of Ethical Conduct for Interactions with Health Care Professionals. APACMed aims to promote close collaboration between the medical technology industry and health care professionals as part of its ongoing mission to improve the standards of care through innovative collaborations among stakeholders. These collaborations are essential to advancing medical technology and ensuring the safe and effective use of members' products and services.

APACMed is committed to ensuring that members' interactions with health care professionals meet the highest ethical standards, preserve independent decision‑making of the health care professional, and reinforce public confidence in the integrity of patient care, treatment, and product and service selection. The Code regulates key aspects of members' interactions with health care professionals including: arrangements with consultants, educational conferences, training and education, research grants and charitable donations. All corporate members are required to adopt, and abide by, the ethical principles outlined in the Code.

"The decision to adopt a universal Code comes from the increasing need for harmonization across Asia Pacific and adapting to the constantly evolving healthcare environment. This is significant for APACMed as it brings us one step closer to providing a clear voice for the industry as we work with stakeholders to jointly shape the future of healthcare together," said Vladimir Makatsaria, Chairman of APACMed.

This new Code will be effective for all APACMed corporate members from 1 January 2016 and will serve to establish the minimum standard by which they operate across Asia Pacific.

Media inquiries can be directed to the APACMed Press Office at [email protected]

About APACMed
The Asia Pacific Medical Technology Association (APACMed) provides a clear voice for the medical devices and in-vitro diagnostics industry in Asia Pacific. Founded in 2014, APACMed strives to promote innovation and impact policy that advances healthcare access for patients. Current members include leading companies in medical technology.
For the full list go to: http://www.apacmed.org/membership

Follow us on:
Twitter: https://twitter.com/apacmed
Facebook: https://www.facebook.com/APACMed
LinkedIn: https://www.linkedin.com/company/asia-pacific-medical-technology-association
Website: http://www.apacmed.org/

Media Contact:

Ashley Lau
Edelman Public Relations Singapore
Tel: +65-6494-1578
Email: [email protected]

 

Source: Asia Pacific Medical Technology Association
Featured Video

Related Keywords:
Health Care/Hospital
Medical Equipment
Medical/Pharmaceuticals
New products/services
Recent Releases
APACMed Implements Universal Code of Ethical Conduct for Corporate Members 2015-12-11
APACMed Kicks Off Asia Pacific MedTech Forum 2015 2015-12-10
Leading Medical Technology Companies Collaborate to Establish Asia Pacific Industry Association Focused on Advancing Patient Care 2015-04-24
Go to MediaRoom
Health Care/Hospital Recent Releases
Honeywell Completes Acquisition of Research Chemicals Business from Sigma-Aldrich 2015-12-15
Concord Medical to Hold Annual General Meeting on December 31, 2015 2015-12-15
WuXi Healthcare Ventures II, L.P. Closes With Oversubscription 2015-12-15
Athenex Announces Recent Business Developments Including the Acquisition of Comprehensive Drug Enterprises 2015-12-15
Value-Based Healthcare Advances the US Remote Patient Monitoring Market 2015-12-14
Read more
Medical Equipment Recent Releases
Medical/Pharmaceuticals Recent Releases
New products/services Recent Releases
 

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.